<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560011</url>
  </required_header>
  <id_info>
    <org_study_id>P160905J</org_study_id>
    <secondary_id>2017-000826-36</secondary_id>
    <nct_id>NCT03560011</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic Syndrome</brief_title>
  <acronym>RITUXIVIG</acronym>
  <official_title>Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic Nephrotic Syndrome (INS) is the first glomerulopathy in children and 60% of the&#xD;
      patients develop Steroid-Dependant Nephrotic Syndrome (SDNS). Recently, rituximab (RTX), a&#xD;
      humanized anti-CD20 antibody depleting B cells demonstrated the ability to increase relapse&#xD;
      free survival and to decrease the number of relapse and the need of other immunosuppressive&#xD;
      drugs. However, the remission rate after 2 years is only 30 to 40%.&#xD;
&#xD;
      The aim of the study is to study the ability of intravenous Immunoglobulin to improve&#xD;
      remission rate in SDNS when added associated with Rituximab compared to a treatment by&#xD;
      Rituximab alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic Nephrotic Syndrome (INS) is the first glomerulopathy in children and 60% of the&#xD;
      patients develop Steroid-Dependant Nephrotic Syndrome (SDNS). Depleting B cells demonstrated&#xD;
      the ability to increase relapse free survival and to decrease the number of relapse and the&#xD;
      need of other immunosuppressive drugs. However, the remission rate after 2 years is only 30&#xD;
      to 40%.&#xD;
&#xD;
      The aim of the study is to study the ability of intravenous Immunoglobulin to improve&#xD;
      remission rate in SDNS when added associated with Rituximab compared to a treatment by&#xD;
      Rituximab alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Decision of Data Safety Monitoring Board&#xD;
  </why_stopped>
  <start_date type="Actual">April 3, 2019</start_date>
  <completion_date type="Anticipated">November 4, 2022</completion_date>
  <primary_completion_date type="Actual">January 7, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 Arms :&#xD;
Rituximab (375 mg/m2)&#xD;
Rituximab (375 mg/m2) followed by 5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dise 100g)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The occurrence of the first relapse</measure>
    <time_frame>24 months</time_frame>
    <description>Relapse is defined as a protein to creatinine ratio of 2g/g of creatinine (0.2 g/mmol) or higher</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first relapse</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapse over a 24 months follow-up</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative amount of corticosteroid over a 24 months follow-up</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events in each arm</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Steroid-Dependent Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Rituximab (375 mg/m²)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Single infusion of rituximab (375 mg/m²)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab followed by 5 injections of immunoglobulin IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab (375 mg/m²) followed by 5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dose 100g). Treatment duration : 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>immunoglobulin IV</intervention_name>
    <description>5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dose 100g)</description>
    <arm_group_label>Rituximab followed by 5 injections of immunoglobulin IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Childhood onset nephrotic syndrome (first flair &lt;18 years)&#xD;
&#xD;
          -  ≥ 2 years old at inclusion&#xD;
&#xD;
          -  Steroid-dependent:&#xD;
&#xD;
               -  Patient with at least 2 relapses confirmed during the decay of corticosteroids or&#xD;
                  within 2 weeks following steroids discontinuation.&#xD;
&#xD;
               -  Patient with at least 2 relapses including one under steroidsparing agent (MMF,&#xD;
                  Calcineurin inhibitors, cyclophosphamide, Levamisole) or within 6 months of&#xD;
                  treatment withdrawal.&#xD;
&#xD;
          -  or with frequent relapses:&#xD;
&#xD;
             · 2 or more relapses within 6 months after initial remission or 4 or more relapses&#xD;
             within any 12-month period.&#xD;
&#xD;
          -  with a relapse within 3 months prior to inclusion&#xD;
&#xD;
          -  In remission: Protein-over-creatinine ratio ≤ 0.2g/g (≤ 0.02g/mmol)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with steroid-resistant nephrotic syndrome;&#xD;
&#xD;
          -  Patients with genetic nephrotic syndrome;&#xD;
&#xD;
          -  Patients previously treated with rituximab;&#xD;
&#xD;
          -  Patients with no affiliation to a social security scheme (beneficiary or legal);&#xD;
&#xD;
          -  Prior Hepatitis B, Hepatitis C or HIV infection;&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Patients with hyperprolinaemia,&#xD;
&#xD;
          -  Known hypersensitivity to one of the study medication,&#xD;
&#xD;
          -  Scheduled and not postponable injection of live attenuated vaccine&#xD;
&#xD;
          -  Protected adults&#xD;
&#xD;
          -  Patients with neutrophils &lt; 1.5 G/L and/or platelets &lt; 75 G/L&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien HOGAN, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert Debre Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 6, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

